Overview
- Late Tuesday the White House announced it was dropping Overton’s nomination after concluding she lacked enough Senate support to win confirmation.
- Opposition came from both Democrats and multiple Senate Republicans who raised questions about her role in proposed changes to childhood vaccine guidance, her stance on flavored vaping authorizations, and her positions on mifepristone dispensing.
- Sen. Bill Cassidy publicly disputed the White House explanation, saying pro‑life Republicans had sought final assurances on abortion‑related policies and that the administration withdrew the nomination rather than provide them.
- Reports say the White House is weighing Sen. Roger Marshall as a possible replacement, but any new nominee faces a compressed lame‑duck window that will make confirmation difficult before January.
- The decision extends a leadership vacuum at the FDA with Acting Commissioner Kyle Diamantas in place, a development that could affect high‑stakes agency reviews such as the mifepristone safety review due in March 2027 and other regulatory decisions.